 Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and BOSTON, May 11, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. We continue to advance our Phase 1 study of FPI-1434, said Chief Executive Officer John Valliant, Ph.D. 